

77813-2

50

CLAIMS:

1. A nucleic acid molecule comprising a nucleic acid sequence which encodes a polypeptide selected from any one of:

(a) SEQ ID Nos: 12 to 16;

(b) an immunogenic fragment comprising at least 12 consecutive amino acids from a polypeptide of (a); and

(c) a polypeptide of (a) or (b) which has been modified without loss of immunogenicity, wherein said modified polypeptide is at least 75% identical in amino acid sequence to the corresponding polypeptide of (a) or (b).

2. A nucleic acid molecule comprising a nucleic acid sequence selected from any one of:

(a) SEQ ID Nos: 3 to 10;

(b) a sequence which encodes a polypeptide encoded by any one of SEQ ID Nos: 3 to 10;

(c) a sequence comprising at least 38 consecutive nucleotides from any one of the nucleic acid sequences of (a) and (b); and

(d) a sequence which encodes a polypeptide which is at least 75% identical in amino acid sequence to any one of the polypeptides encoded by SEQ ID Nos: 3 to 10.

3. A nucleic acid molecule comprising a nucleic acid sequence which is anti-sense to the nucleic acid molecule of claim 1 or 2.

4. A nucleic acid molecule comprising a nucleic acid sequence which encodes a fusion protein, said fusion protein

77813-2

51

comprising a first polypeptide and a second polypeptide,
wherein the first polypeptide is selected from any one of:

(a) SEQ ID Nos: 11-16;

(b) an immunogenic fragment comprising at least 12
5 consecutive amino acids from a polypeptide of SEQ ID Nos: 11-
16; and

(c) a polypeptide of (a) or (b) which has been
modified without loss of immunogenicity, wherein said modified
polypeptide is at least 75% identical in amino acid sequence to
10 the corresponding polypeptide of (a) or (b).

5. The nucleic acid molecule of claim 4 wherein the
second polypeptide is a heterologous signal peptide.

6. The nucleic acid molecule of claim 4 wherein the
second polypeptide has adjuvant activity.

15 7. A nucleic acid molecule according to any one of
claims 1 to 6, operatively linked to one or more expression
control sequences.

8. A vaccine comprising a vaccine vector and at least
one first nucleic acid selected from any of:

20 (i) SEQ ID Nos: 1 to 10;

(ii) a nucleic acid sequence which encodes a
polypeptide encoded by any one of SEQ ID Nos: 1 to 10;

(iii) a nucleic acid sequence comprising at least 38
consecutive nucleotides from any one of the nucleic acid
25 sequences of (i) and (ii);

(iv) a nucleic acid sequence which encodes a
polypeptide which is at least 75% identical in amino acid

77813-2

52

Cont
Q2
sequence to the polypeptide encoded by any one of SEQ ID Nos: 1 to 10;

(v) a nucleic acid sequence which encodes a polypeptide whose sequence is set forth in any one of SEQ ID Nos: 11 to 16;

(vi) a nucleic acid sequence which encodes an immunogenic fragment comprising at least 12 consecutive amino acids from any one of SEQ ID Nos: 11 to 16; and

(vii) a nucleic acid sequence which encodes a polypeptide as defined in (i) to (v) or an immunogenic fragment as defined in (vi) which has been modified without loss of immunogenicity, wherein said modified polypeptide or fragment is at least 75% identical in amino acid sequence to the corresponding polypeptide of (i) to (v) or the corresponding fragment of (vi);

wherein each first nucleic acid is capable of being expressed and wherein the vaccine optionally comprises a second nucleic acid encoding and capable of expressing an additional polypeptide which enhances the immune response to the polypeptide expressed by the first nucleic acid.

9. A vaccine comprising a vaccine vector and at least one first nucleic acid encoding a fusion protein, wherein the fusion protein comprises:

(a) a first polypeptide selected from any of:

(i) a polypeptide encoded by any one of SEQ ID Nos: 1 to 10;

(ii) a polypeptide encoded by a nucleic acid sequence comprising at least 38 consecutive nucleotides from any one of SEQ ID Nos: 1 to 10;

77813-2

53

Ant
A2
(iii) a polypeptide which is at least 75% identical in amino acid sequence to the polypeptide encoded by any one of SEQ ID Nos: 1 to 10;

(iv) a polypeptide whose sequence is set forth in any one of SEQ ID Nos: 11 to 16;

(v) an immunogenic fragment comprising at least 12 consecutive amino acids from any one of SEQ ID Nos: 11 to 16; and

(vi) a polypeptide as defined in (i) to (iv) or an immunogenic fragment as defined in (v) which has been modified without loss of immunogenicity, wherein said modified polypeptide or fragment is at least 75% identical in amino acid sequence to the corresponding polypeptide of (i) to (iv) or the corresponding fragment of (v); and

(b) a second polypeptide;

wherein each first nucleic acid is capable of being expressed and wherein the vaccine optionally comprises a second nucleic acid encoding and capable of expressing an additional polypeptide which enhances the immune response to the first polypeptide.

10. The vaccine of claim 9 wherein the second polypeptide is a heterologous signal peptide.

11. The vaccine of claim 9 wherein the second polypeptide has adjuvant activity.

12. The vaccine of any one of claims 8 to 11 wherein wherein each first nucleic acid is operatively linked to one or more expression control sequences.

13. A vaccine comprising at least one first nucleic acid according to any one of claims 1, 2, and 4 to 7 and a vaccine

77813-2

54

But
A3
vector wherein each first nucleic acid is expressed as a polypeptide, the vaccine optionally comprising a second nucleic acid encoding an additional polypeptide which enhances the immune response to the polypeptide expressed by said first
5 nucleic acid.

14. The vaccine of any one of claims 8 to 13 wherein the second nucleic acid encodes an additional *Chlamydia* polypeptide.

15. A pharmaceutical composition comprising a nucleic acid according to any one of claims 1 to 7 and a
10 pharmaceutically acceptable carrier.

16. A pharmaceutical composition comprising a vaccine according to any one of claims 8 to 14 and a pharmaceutically acceptable carrier.

15 17. A unicellular host transformed with the nucleic acid molecule of claim 7.

18. An isolated nucleic acid probe of 5 to 100 nucleotides which hybridizes under stringent conditions to the nucleic acid molecule of any one of SEQ ID Nos: 3 to 10, or to
20 a complementary or anti-sense sequence of said nucleic acid molecule.

Sub
C6
19. An isolated primer of 10 to 40 nucleotides which hybridizes under stringent conditions to the nucleic acid molecules of any one of SEQ ID Nos: 3 to 10, or to a
25 complementary or anti-sense sequence of said nucleic acid molecule.

Sub
A4
20. A polypeptide encoded by a nucleic acid sequence according to any one of claims 1, 2 and 4 to 7.

77813-2

55

21. A polypeptide comprising an amino acid sequence selected from any of:

(a) SEQ ID Nos: 12 to 16;

(b) an immunogenic fragment comprising at least 12 consecutive amino acids from a polypeptide of (a); and

(c) a polypeptide of (a) or (b) which has been modified without loss of immunogenicity, wherein said modified polypeptide is at least 75% identical in amino acid sequence to the corresponding polypeptide of (a) or (b).

22. A fusion polypeptide comprising a first polypeptide and a second polypeptide, wherein the first polypeptide is selected from any one of:

(a) a polypeptide encoded by any one of SEQ ID Nos: 1 to 10;

(b) a polypeptide encoded by a nucleic acid sequence comprising at least 38 consecutive nucleotides from any one of SEQ ID Nos: 1 to 10;

(c) a polypeptide which is at least 75% identical in amino acid sequence to the polypeptide encoded by any one of SEQ ID Nos: 1 to 10;

(d) a polypeptide whose sequence is set forth in any one of SEQ ID Nos: 11 to 16;

(e) an immunogenic fragment comprising at least 12 consecutive amino acids from any one of SEQ ID Nos: 11 to 16;

and

(f) a polypeptide as defined in (a) to (d) or an immunogenic fragment as defined in (e) which has been modified without loss of immunogenicity, wherein said modified

77813-2

56

polypeptide or fragment is at least 75% identical in amino acid sequence to the corresponding polypeptide of (a) to (d) or the corresponding fragment of (e).

23. The fusion protein of claim 22 wherein the second
5 polypeptide is a heterologous signal peptide.

24. The fusion protein of claim 22 wherein the second polypeptide has adjuvant activity.

Subst
25. A method for producing a polypeptide of claim 20 or
10 21, or a fusion protein of any one of claims 22 to 24,
comprising the step of culturing a unicellular host of claim
17.

26. An antibody against the polypeptide of claim 20 or
21, or against a fusion protein of any one of claims 22 to 24.

27. A vaccine comprising at least one first polypeptide
15 selected from any of:

(i) a polypeptide encoded by any one of SEQ ID Nos: 1
to 10;

(ii) a polypeptide encoded by a nucleic acid sequence
comprising at least 38 consecutive nucleotides from any one of
20 SEQ ID Nos: 1 to 10;

(iii) a polypeptide which is at least 75% identical
in amino acid sequence to the polypeptide encoded by any one of
SEQ ID Nos: 1 to 10;

(iv) a polypeptide whose sequence is set forth in any
25 one of SEQ ID Nos: 11 to 16;

(v) an immunogenic fragment comprising at least 12
consecutive amino acids from any one of SEQ ID Nos: 11 to 16;
and

77813-2

57

Ortho
AS

(vi) a polypeptide as defined in (i) to (iv) or an immunogenic fragment as defined in (v) which has been modified without loss of immunogenicity, wherein said modified polypeptide or fragment is at least 75% identical in amino acid sequence to the corresponding polypeptide of (i) to (iv) or the corresponding fragment of (v);

wherein the vaccine optionally comprises an additional polypeptide which enhances the immune response to the first polypeptide.

10 28. A vaccine comprising at least one fusion protein, wherein the fusion protein comprises:

(a) a first polypeptide selected from any of:

(i) a polypeptide encoded by SEQ ID No: 1;

15 (ii) a polypeptide encoded by a nucleic acid sequence comprising at least 38 consecutive nucleotides from SEQ ID No: 1;

(iii) a polypeptide which is at least 75% identical in amino acid sequence to the polypeptide encoded by SEQ ID No: 1;

20 (iv) a polypeptide whose sequence is set forth in SEQ ID No: 2;

(v) an immunogenic fragment comprising at least 12 consecutive amino acids from SEQ ID No: 2; and

25 (vi) a polypeptide as defined in (i) to (iv) or an immunogenic fragment as defined in (v) which has been modified without loss of immunogenicity, wherein said modified polypeptide or fragment is at least 75% identical in amino acid sequence to the corresponding polypeptide of (i) to (iv) or the corresponding fragment of (v); and

77813-2

58

(b) a second polypeptide;

wherein the vaccine optionally comprises an additional polypeptide which enhances the immune response to the first polypeptide.

5 29. The vaccine of claim 28 wherein the second polypeptide is a heterologous signal peptide.

30. The vaccine of claim 28 wherein the second polypeptide has adjuvant activity.

10 31. A vaccine comprising at least one first polypeptide according to any one of claims 20 to 24, optionally comprising an additional polypeptide which enhances the immune response to the first polypeptide.

32. The vaccine of any one of claims 27 to 31 wherein the additional polypeptide comprises a *Chlamydia* polypeptide.

15 33. A pharmaceutical composition comprising a polypeptide according to any one of claims 20 to 24 and a pharmaceutically acceptable carrier.

20 34. A pharmaceutical composition comprising a vaccine according to any one of claims 27 to 32 and a pharmaceutically acceptable carrier.

35. A pharmaceutical composition comprising an antibody according to claim 26 and a pharmaceutically acceptable carrier.

25 36. A method for preventing or treating *Chlamydia* infection using:

(a) the nucleic acid of any one of claims 1 to 7;

77813-2

59

Part
a?
to 32;

(b) the vaccine of any one of claims 8 to 14 and 27

(c) the pharmaceutical composition of any one of claims 15, 16 and 33 to 35;

5 (d) the polypeptide of claim 20 or 21, or a fusion protein of any one of claims 22 to 24; or

(e) the antibody of claim 26.

37. A method of detecting *Chlamydia* infection comprising the step of assaying a body fluid of a mammal to be tested, with a component selected from any one of:

(a) the nucleic acid of any one of claims 1 to 7;

(b) the polypeptide of claim 20 or 21, or a fusion protein of any one of claims 22 to 24; and

(c) the antibody of claim 26.

15 38. A diagnostic kit comprising instructions for use and a component selected from any one of:

(a) the nucleic acid of any one of claims 1 to 7;

(b) the polypeptide of claim 20 or 21, or a fusion protein of any one of claims 22 to 24; and

20 (c) the antibody of claim 26.

39. A method for identifying a polypeptide of claim 20 or 21, or a fusion protein of any one of claims 22 to 24 which induces an immune response effective to prevent or lessen the severity of *Chlamydia* infection in a mammal previously immunized with polypeptide, comprising the steps of:

Sub A?

60

(b) ~~inoculating~~ the immunized mouse with *Chlamydia*;

wherein the polypeptide or fusion protein which prevents or
5 lessens the severity of *Chlamydia* infection in the immunized
mouse compared to a non-immunized control mouse is identified.

Year	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100
1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034	2035	2036	2037	2038	2039	2040	2041	2042	2043	2044	2045	2046	2047	2048	2049	2050	2051	2052	2053	2054	2055	2056	2057	2058	2059	2060	2061	2062	2063	2064	2065	2066	2067	2068	2069	2070	2071	2072	2073	2074	2075	2076	2077	2078	2079	2080	2081	2082	2083	2084	2085	2086	2087	2088	2089	2090	2091	2092	2093	2094	2095	2096	2097	2098	2099	2100	